Ten treatment measures for IgA nephropathy

doi:10.3877/cma.j.issn.2095-3216.2024.06.005

Abstract

Abstract:

IgA nephropathy is an autoimmune disease characterized by IgA-predominant deposition of immunoglobulins in the mesangial area the glomeruli， accompanied by mesangial cell proliferation and mesangial matrix expansion. Currently， there is no unified treatment regimen for IgA nephropathy. In the treatment process， it is necessary to consider the patients’ clinical manifestations， renal pathological changes， and the pathogenesis of the disease. Balancing efficacy and safety， personalized diagnosis and treatment should be provided to the patients. In recent years， with an increasing understanding of the autoimmune pathogenesis of IgA nephropathy， the combined use of traditional medications and various novel agents targeting different pathways can complement each other mechanistically to achieve precise individualized control of the disease， thereby improving renal outcomes. This article systematically summerized the ten treatment measures for IgA nephropathy and the respective action mechanisms of relevant drugs， aiming to deepen understanding of IgA nephropathy treatment and provide guidance for clinical practice.

Key words: IgA nephropathy, Treatment, Progress

Wenkai Guo, Pengcheng Ji, Jingru Bi, Yuansheng Xie. Ten treatment measures for IgA nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 327-333.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2024.06.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2024/V13/I06/327

References 71

［1］	Xie Y， Chen X. Epidemiology， major outcomes， risk factors，prevention and management of chronic kidney disease in China［J］. Am J Nephrol，2008，28（1）：1-7.
［2］	Kidney Disease： Improving Global Outcomes （ KDIGO ）Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases ［J］.Kidney Int，2021，100（4S）： S1-S276.
［3］	Pattrapornpisut P， Avila-Casado C， Reich HN. IgA nephropathy： core curriculum 2021 ［J］. Am J Kidney Dis，2021，78（3）：429-441.
［4］	Tang C， Chen P， Si FL， et al. Time-varying proteinuria and progression of IgA nephropathy： a cohort study ［J］. Am J Kidney Dis，2024，84（2）：170-178.e1.
［5］	Praga M， Gutiérrez E， González E， et al. Treatment of IgA nephropathy with ACE inhibitors： a randomized and controlled trial ［J］. J Am Soc Nephrol，2003，14（6）：1578-1583.
［6］	Li PK， Leung CB， Chow KM， et al. Hong Kong study using valsartan in IgA nephropathy （ HKVIN）： a double-blind，randomized， placebo-controlled study ［J］. Am J Kidney Dis，2006，47（5）：751-760.
［7］	Zhao Y， Fan H， Bao BY. Efficacy and safety of reninangiotensin aldosterone system inhibitor in patients with IgA nephropathy： a meta-analysis of randomized controlled trials［J］. Iran J Public Health，2019，48（9）：1577-1588.
［8］	Heerspink HJL， Stefánsson BV， Correa-Rotter R， et al.Dapagliflozin in patients with chronic kidney disease［J］. N Engl J Med，2020，383（15）：1436-1446.
［9］	Wheeler DC， Toto RD， Stefánsson BV， et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy ［J］. Kidney Int，2021，100（1）：215-224.
［10］	Del Vecchio L， Beretta A， Jovane C， et al. A role for SGLT-2 Inhibitors in treating non-diabetic chronic kidney disease ［J］.Drugs，2021，81（13）：1491-1511.
［11］	Herrington WG， Staplin N， Wanner C， et al. Empagliflozin in patients with chronic kidney disease ［J］. N Engl J Med，2023，388（2）：117-127.
［12］	Nirk EL， Reggiori F， Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond ［J］. EMBO Mol Med，2020，12（8）： e12476.
［13］	Lee M， Suzuki H， Ogiwara K， et al. The nucleotide-sensing Toll-like receptor 9/Toll-like receptor 7 system is a potential therapeutic target for IgA nephropathy ［J］. Kidney Int， 2023，104（5）：943-955.
［14］	Schrezenmeier E， Dörner T. Mechanisms of action of hydroxychloroquineandchloroquine：implicationsfor rheumatology ［J］. Nat Rev Rheumatol， 2020， 16（3）： 155-166.
［15］	Liu LJ， Yang YZ， Shi SF， et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy： a randomized controlled trial［J］. Am J Kidney Dis，2019，74（1）：15-22.
［16］	Yang YZ， Liu LJ， Shi SF， et al. Effects of hydroxychloroquine on proteinuria in immunoglobulin a nephropathy ［J］. Am J Nephrol，2018，47（3）：145-152.
［17］	Beck LH Jr， Ayoub I， Caster D， et al. KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of glomerular diseases ［J］. Am J Kidney Dis，2023，82（2）：121-175.
［18］	Ding HJ， Denniston AK， Rao VK， et al. Hydroxychloroquinerelated retinal toxicity ［J］. Rheumatology （Oxford）， 2016， 55（6）：957-967.
［19］	中国医药卫生文化协会肾病与血液净化专业委员会. 原发性IgA 肾病管理和治疗中国专家共识［J/CD］. 中华肾病研究电子杂志，2024，13（1）：1-8.
［20］	Kohan DE， Barton M. Endothelin and endothelin antagonists in chronic kidney disease ［J］. Kidney Int， 2014， 86（5）： 896-904.
［21］	Komers R， Plotkin H. Dual inhibition of renin-angiotensinaldosterone system and endothelin-1 in treatment of chronic kidney disease ［J］. Am J Physiol Regul Integr Comp Physiol，2016，310（10）： R877-R884.
［22］	Rovin BH， Barratt J， Heerspink HJL， et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy（ PROTECT）： 2-year results from a randomised， activecontrolled， phase 3 trial ［J］. Lancet， 2023， 402（10417）：2077-2090.
［23］	Heerspink HJL， Radhakrishnan J， Alpers CE， et al. Sparsentan in patients with IgA nephropathy： a prespecified interim analysis from a randomised， double-blind， active-controlled clinical trial［J］. Lancet，2023，401（10388）：1584-1594.
［24］	Pei GQ， Tian JX， Tang Y， et al. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria ［ J］. Medicine（Baltimore），2020，99（24）： e20513.
［25］	Pozzi C， Andrulli S， Del Vecchio L， et al. Corticosteroid effectiveness in IgA nephropathy： long term results of a randomized， controlled trial ［J］. J Am Soc Nephrol， 2004， 15（1）：157-163.
［26］	Lv J， Wong MG， Hladunewich MA， et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy： the TESTING randomized clinical trial ［ J］.JAMA，2017，318（5）：432-442.
［27］	Lv J， Wong MG， Hladunewich MA， et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy： the TESTING randomized clinical trial ［J］. JAMA，2022，327（19）：1888-1898.
［28］	Rauen T， Eitner F， Fitzner C， et al. Intensive supportive care plus immunosuppression in IgA nephropathy［J］. N Engl J Med，2015，373（23）：2225-2236.
［29］	Fellström BC， Barratt J， Cook H， et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy（NEFIGAN）： a double-blind， randomised， placebo-controlled phase 2b trial ［J］. Lancet，2017，389（10084）：2117-2127.
［30］	Lafayette R， Kristensen J， Stone A， et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy （NefIgArd）： 2-year results from a randomised phase 3 trial ［J］. Lancet， 2023， 402（10405）：859-870.
［31］	Suzuki H， Kiryluk K， Novak J， et al. The pathophysiology of IgA nephropathy［J］. J Am Soc Nephrol，2011，22（10）：1795-1803.
［32］	Mestecky J， Raska M， Julian BA， et al. IgA nephropathy：molecular mechanisms of the disease ［J］. Annu Rev Pathol，2013，8：217-240.
［33］	Allison AC，EuguiEM.Purinemetabolismand immunosuppressive effects of mycophenolate mofetil （MMF）［J］. Clin Transplant，1996，10（1 Pt 2）：77-84.
［34］	Hou FF， Xie D， Wang J， et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA Nephropathy： a randomized clinical trial ［J］. JAMA Netw Open， 2023， 6（2）：e2254054.
［35］	Zhao H， Li Y， Sun J， et al. Immunosuppression versus supportive care on kidney outcomes in IgA nephropathy in the real-world setting ［J］. Clin J Am Soc Nephrol， 2023， 18（9）：1186 -1194.
［36］	陈香美，陈仆，蔡广研，等. 麦考酚酸酯治疗IgA 肾病的随访对照观察［J］. 中华医学杂志，2002，82（12）：796-801.
［37］	Peng XJ， Zheng WM， Fu R， etal. Efficacy and safety of mycophenolate mofetil in the？ treatment for IgA nephropathy： a meta-analysis of randomized controlled trials ［J］. Clin Exp Nephrol，2021，25（7）：788-801.
［38］	Takahashi S， Wakui H， Gustafsson JA. et al. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein ［J］. Biochem Biophys Res Commun， 2000， 274（1）：87-92.
［39］	Xie Y， Huang S， Wang L， et al. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy： a multicenter， randomized， controlled study ［J］.Am J Med Sci，2011，341（5）：367-372.
［40］	Kawasaki Y， Suzuki J， Sakai N， et al. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy ［J］. Am J Nephrol，2004，24（1）：147-153.
［41］	Du W， Chen Z， Fang Z， et al. Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis［J］. Clin Kidney J，2023，16（12）：2567-2577.
［42］	Xu L， Liu ZC， Guan GJ， et al. Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy［J］. Kaohsiung J Med Sci，2014，30（8）：390-395.
［43］	Zhang Y， Luo J， Hu B， et al. Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy： a meta-analysis ［J］. J Int Med Res，2018，46（8）：3236-3250.
［44］	Breedveld FC， Dayer JM. Leflunomide： mode of action in the treatment of rheumatoid arthritis ［J］. Ann Rheum Dis， 2000，59（11）：841-849.
［45］	Carrión-Barberà I， Polino L， Mejía-Torres M， et al.Leflunomide： a safe and effective alternative in systemic lupus erythematosus ［J］. Autoimmun Rev，2022，21（2）：102960.
［46］	He WJ， Wang J， Liu N， et al. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy： a single-center experience ［J］. J Nephrol， 2024，37（4）：933-940.
［47］	Zhang D，Xia B，Zhang X，et al. Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy： a systematic review and meta-analysis ［J］. BMC Urol，2024，24（1）：56.
［48］	董玉，尚顺来，李清刚，等. 来氟米特联合甲泼尼龙治疗IgA肾病的疗效观察［J/CD］. 中华肾病研究电子杂志， 2020， 9（3）：102-106.
［49］	陈玉贞，徐家云. 来氟米特联合中小剂量糖皮质激素治疗慢性进展性IgA 肾病的疗效及安全性分析［J/CD］. 中华肾病研究电子杂志，2019，8（5）：208-212.
［50］	Yi J， He Z， Xu S， et al. Efficacy and safety of leflunomide in IgA nephropathy：a systematic review and meta-analysis［J］. Int Urol Nephrol，2019，51（11）：1987-1998.
［51］	常美莹，赵明明，余怡，等. 雷公藤多苷片联合ACEI/ARB治疗IgA 肾病蛋白尿的回顾性研究［J］. 世界中西医结合杂志，2022，17（10）：2035-2038，2043.
［52］	李文文，刘晓丽，吴颢，等. 雷公藤治疗IgA 肾病疗效和安全性的Meta 分析［J］. 中国循证医学杂志， 2015， 15（2）：206-214.
［53］	Zhao N， Hou P， Lv J， et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression ［J］. Kidney Int， 2012， 82（7）： 790-796.
［54］	Castigli E， Scott S， Dedeoglu F， et al. Impaired IgA class switching in APRIL-deficient mice ［J］. Proc Natl Acad Sci USA，2004，101（11）：3903-3908.
［55］	Cheung CK， Barratt J， Carroll K， et al. Targeting APRIL in the treatment of IgA nephropathy ［J］. Clin J Am Soc Nephrol，2024，19（3）：394-398.
［56］	Zhai YL， Zhu L， Shi SF， et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy ［J］.Medicine （Baltimore），2016，95（11）： e3099.
［57］	Mathur M， Barratt J， Chacko B， et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy ［J］. N Engl J Med，2024，390（1）：20-31.
［58］	Gross JA， Johnston J， Mudri S， et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease ［J］. Nature，2000，404（6781）：995-999.
［59］	Barratt J， Tumlin J， Suzuki Y， et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria ［J］. Kidney Int Rep，2022，7（8）：1831-1841.
［60］	Lv J， Liu L， Hao C， et al. Randomized phase 2 trial of telitacicept in patients with IgA Nephropathy with persistent proteinuria ［J］. Kidney Int Rep，2023，8（3）：499-506.
［61］	Zhang H， Rizk DV， Perkovic V， et al. Results of a randomized double-blindplacebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy ［J］. Kidney Int，2024，105（1）：189-199.
［62］	Barratt J， Liew A， Yeo SC， et al. Phase 2 trial of cemdisiran in adult patients with IgA nephropathy：a randomized controlled trial［J］. Clin J Am Soc Nephrol，2024，19（4）：452 -462.
［63］	中国中西医结合学会肾脏疾病专业委员会. IgA 肾病西医诊断和中医辨证分型的实践指南［J］. 中国中西医结合杂志，2013，33（5）：583 -585.
［64］	卢登勇，石晓冬，陈宇珊，等. 中医药治疗免疫球蛋白A 肾病系统评价/Meta 分析的再评价［J］. 中医临床研究， 2022，14（11）：135 -138.
［65］	Zhang L， Li P， Xing CY， et al. Efficacy and safety of Abelmoschus manihot for primary glomerular disease： a prospective， multicenter randomized controlled clinical trial ［J］.Am J Kidney Dis，2014，64（1）：57-65.
［66］	Li P， Lin H， Ni Z， et al. Efficacy and safety of Abelmoschus manihot for IgA nephropathy： a multicenter randomized clinical trial ［J］. Phytomedicine，2020，76：153231.
［67］	徐艺，胡豪飞，许日聪，等. IgA 肾病扁桃体淋巴细胞亚群与患者蛋白尿的相关性分析［J］. 中国中西医结合肾病杂志，2022，23（6）：499 -502.
［68］	Xie Y， Nishi S， Ueno M， et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy ［J］.Kidney Int，2003，63（5）：1861-1867.
［69］	XieY， Chen X， Nishi S， et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy ［J］.Kidney Int，2004，65（4）：1135-1144.
［70］	Kawamura T， Yoshimura M， Miyazaki Y， et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy［J］. Nephrol Dial Transplant，2014，29（8）：1546-1553.
［71］	Liu LL， Wang LN， Jiang Y， et al. Tonsillectomy for IgA nephropathy： a meta-analysis ［J］. Am J Kidney Dis，2015，65（1）：80-87.

[1]	Baicheng Yi, Xuguang Li, Rongrong Wang, Xinxuan Wang. Treatment of calcified root canals in upper anterior teeth using digital 3D-printing guides：A clinical report of two cases [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(06): 385-390.
[2]	Huayue Yan, Zixiang Liu, Shaobo Zhou. Research progress of phosphoenolpyruvate carboxykinase-1 in malignant tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 452-456.
[3]	Huazhi Li, Guang Cao, Diangang Liu, Yajing Zhang. Clinical comparison of descending hepatectomy with different approaches for primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 52-55.
[4]	Hao Chen, Meng Wang. Advances in clinicopathological features and treatment options of sig-ring cell carcinoma of the stomach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 108-111.
[5]	Lian Sun, Hongping Ma, Wenying Wu. Surgical management of patients with locally advanced thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 112-114.
[6]	Yuefang Xu, Wang Liu, Miaotian Zeng, Yushu Guo. Clinical efficacy of polymyxin B and polymyxin E in the treatment of surgical multi-drug resistant infections Security analysis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 700-703.
[7]	Qiusheng Wang. Diagnosis and treatment strategy for benign biliary diseases [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 779-782.
[8]	Yifan Li, Diwen Zhu, Weixin Ren, Yingjun Bao, Junpeng Gu, Haixiao Zhang, Gengfei Cao, Weizheng Ji. Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 825-830.
[9]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[10]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[11]	Xuefeng Zhou, Zheyi Dong, Zhe Feng, Guangyan Cai, Xiangmei Chen. Formulation protocol of guidelines for diagnosis and treatment of diabetic kidney disease with integrated traditional Chinese and Western medicine [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 301-305.
[12]	Bin Shi, Yuan Si. Effect of Yiqiheluo formula combined with valsartan in the treatment of IgA nephropathy with deficiency of both qi and yin plus blood stasis syndrome [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 306-312.
[13]	Tianyu Wu, Zixuan Liu, Puxin Yang, Siming Jia, Kai Ding, Xiaodong Cheng, Yonglong Li, Wei Chen, Hongzhi Lyu, Qi Zhang. Progress in Conservative Treatment of Lumbar Disc Herniation [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 379-384.
[14]	Qi Liu, Shoukai Wang, Shuai Wang, Yuqing Su, Zhuang Ma, Haijun Chen, Pilei Si. Advances in research of intratumoral microbiome in breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 841-845.
[15]	Hongji Ding, Changjiang Zhao, Pengfei Sun, Can Wang, Guizhen Wang, Longlong Li. Progress in understanding relationship between pyroptosis and diseases [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 682-686.

Please choose a citation manager

Content to export